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LETTERS
Individualised surveillance
strategies for colorectal cancer in
inflammatory bowel disease
We read with interest the updated guidelines
for colorectal cancer (CRC) screening and
surveillance in moderate and high risk groups
from Cairns SR et al.1 Indeed risk stratifica-
tion is an important step forward for
inflammatory bowel disease (IBD)-related
CRC surveillance programmes. But as the
authors already suggest, the adherence to
these surveillance protocols is poor and,
furthermore, the proposed strategy is based
on risk factors originating from tertiary
referral centres with high-risk patients
groups. It has already been demonstrated by
population-based studies that there might
have been an overestimated risk of IBD-
related CRC.2 In a Dutch nested casee
control study including 173 cases and 393
control patients, we identified several strong
prognostic factors for IBD-related CRC in
general hospitals: age, duration of primary
sclerosing cholangitis (PSC) and IBD,
concomitant pseudopolyps and use of anti-
tumour necrosis factor or immunosuppres-
sives.3 We used Poisson regression of time to
CRC with time-dependent covariates in
these data to estimate the individual CRC
risk for patient with IBD.
The different factors were weighted by
their regression coefficients and subse-
quently assigned rounded figures. For
example: 3 years of PSC and 4 years of IBD
both received one point in the prediction rule
(table 1). Practical use of the model is illus-
trated with a hypothetical 50-year-old male
patient, diagnosed with IBD at age 22,
extensive colitis with pseudopolyps,
concomitant PSC for 10 years. According to
table 1, his age score is five points, and total
sum is 22 points. His probability for the
development of CRC in the next year is 0.2%
(figure 1).
Although this proposed model needs to
be validated in an external cohort, we
believe that is a first, important step
towards individualised surveillance for
patients with IBD and can be applied in
general hospitals. According to this model
we would propose to start surveillance
every 3 years in patients with IBD with
a predicted risk of 0.2% or higher. After
further validation, this model may support
physicians in deciding on starting surveil-
lance in general hospitals.
Judith E Baars,1 Caspar W N Looman,2
Ewout W Steyerberg,2 Ernst J Kuipers,1,3
Christien J van der Woude1
1Department of Gastroenterology and Hepatology,
Erasmus MC, Rotterdam, The Netherlands; 2Department
of Public Health, Erasmus MC, Rotterdam, The
Netherlands; 3Department of Internal Medicine, Erasmus
MC, Rotterdam, The Netherlands
Correspondence to Dr J E Baars, Department of
Gastroenterology and Hepatology, Erasmus MC, ’s
Gravendijkwal 230, Room Ba 393, 3015 CE Rotterdam,
The Netherlands; j.baars@erasmusmc.nl
Competing interests None.
Contributors Specific author contributions: Conception
and design: CJvdW, JEB. Collection and assembly of
data: JEB. Data analysis and interpretation: JEB, CWNL,
EWS, CJvdW. Manuscript writing: JEB, CWNL, EWS,
EJK, CJvdW. Final approval of manuscript: JEB, CWNL,
EWS, CJvdW, EJK.
Provenance and peer review Not commissioned; not
externally peer reviewed.
Published Online First 13 December 2010
Gut 2011;60:739. doi:10.1136/gut.2010.229351
REFERENCES
1. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines
for colorectal cancer screening and surveillance in
moderate and high risk groups (update from 2002). Gut
2010;59:666e89.
2. Lakatos PL, Lakatos L. Risk for colorectal cancer in
ulcerative colitis: changes, causes and management
strategies. World J Gastroenterol 2008;14:3937e47.
3. Baars JE, Looman CW, Steyerberg EW, et al. The risk of
inflammatory bowel disease related colorectal
carcinoma is limited: results from a nationwide nested
case-control study. Am J Gastroenterol
2011;106:319e28.
Efficacy of azathioprine versus
mesalazine in postoperative
Crohn’s diseaseeThe Authors’
response
We thank Dr Ford for his comments1 on our
recent paper in Gut entitled ‘Azathioprine
versus mesalazine for prevention of post-
operative clinical recurrence in patients with
Table 1 Prediction model flowchart
Step 1: Choose the number of points for each patient characteristic mentioned below:
Patient’s characteristics No. of points
Duration of IBD 1 point for every 4 years of IBD
Duration of PSC 1 point for every 3 years of PSC
Gender
Male 2 points
Female 0 points
Location of IBD
Leftsided colitis (UC) 0 points
Extensive colitis (UC) 1 point
Limited CD 3 points
Extensive CD 1 point
Unclassified colitis 0 points
Concomitant pseudopolyps 4 points
Step 2: Choose the number of points that matches with your patient’s age:
Age Points Age Points
0e6 10 37e50 6
7e9 9 51e53 7
10e12 8 54 8
13e14 7 55 9
15e17 6 56 10
18e20 5 57 11
21e23 4 58 13
24e25 3 59 14
26e27 2 60 15
28e29 1 61 16
30 0 62 18
31 1 63 19
32e33 2 64 20
34 3 65 22
35 4
36 5
Step 3: From figure 1 read your patient’s individual risk for developing inflammatory bowel disease-related
colorectal cancer within the next year
Figure 1 Individualised risk of developing
inflammatory bowel disease-related colorectal
cancer.
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